Record ID: MS-N073 · Family: Cannabis / supportive care / immunotherapy interaction · Clinical question: Does cannabis use alter checkpoint-inhibitor response, progression or survival?
Evidence label: Conflicting observational evidence; no causal proof that cannabis worsens or improves immunotherapy outcomes.
Evidence at a glance
- Benefit: Cannabis may be used for selected symptoms, but it is not established as a way to improve immunotherapy.
- Certainty: Very low for treatment interaction because exposure was not randomized and confounding is substantial.
- Risk: One small prospective cohort reported markedly worse outcomes; a larger pooled analysis did not confirm harm.
- Cancer control: Progression and survival were studied, but observational associations cannot establish an anticancer or antagonistic effect.
What was studied
A prospective observational study followed 102 people with advanced cancers: 68 received immune-checkpoint inhibitors without cannabis and 34 reported concomitant cannabis. Recruitment stopped early after an interim analysis, short of the planned 243 participants.
A 2025 pooled individual-participant analysis included 684 participants from four Canadian Cancer Trials Group studies of dual checkpoint inhibition with or without chemotherapy; 65 were ever-users and 32 reported baseline cannabis use.
What the results show
In the 102-person cohort, median time to progression was 3.4 months with cannabis versus 13.1 months without, and median overall survival was 6.4 versus 28.5 months. Adjusted hazards were 1.95 for progression (95% CI 1.17–3.26) and 2.18 for death (95% CI 1.24–3.82).
In the 684-person pooled analysis, baseline use was associated with improved immune-related progression-free survival at the prespecified boundary (P=.05), but not response, conventional progression-free survival, overall survival (P=.35), or immune-related adverse events. A 2025 systematic review concluded that the evidence remained observational and insufficient for a firm interaction claim.
Important limits
- People using cannabis may have had worse symptoms, more advanced illness or different supportive needs—classic confounding by indication.
- Cancer types, products, THC/CBD content, route, dose and timing varied.
- The smaller study stopped early, which can magnify unstable estimates.
- No trial randomized cannabis exposure; funding and conflicts are available in the original reports but were not fully re-extracted here.
Safety and practical context
Separate symptom management from cancer-control claims. Cannabis can cause sedation, dizziness, cognitive impairment, falls, anxiety, vomiting and drug interactions; inhaled products add pulmonary exposure. Discuss the exact formulation and route with the oncology team.
Questions for the care team
- What symptom is cannabis intended to treat?
- What are the THC/CBD content, route, dose and timing?
- Could sedation, anticoagulants, other medicines or driving make use unsafe?
- How will response to immunotherapy be assessed without attributing changes to cannabis?
Sources checked
- Bar-Sela et al., prospective observational cohort, 2020 (PMID 32872248; PMCID PMC7563978).
- CCTG pooled individual-participant analysis, 2025 (PMID 40184324).
- Systematic review of cannabis and immune-checkpoint inhibitor outcomes, 2025 (PMID 39921765).
- ASCO guideline on cannabis and cannabinoids in adults with cancer, 2024 (PMID 38478773).
Last literature search: October 19, 2026 · Record appraisal: October 19, 2026
Educational information only. This record is not a prescription and does not replace advice from the oncology team or oncology pharmacist.
